产品
编 号：F380023
分子式：C20H24N2O7
分子量：404.41
分子式：C20H24N2O7
分子量：404.41
产品类型
规格
价格
是否有货
结构图
CAS No: 527680-57-5
产品详情
生物活性：
PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.
体内研究：
PHA 568487 attenuates neuronal injury and behavioral dysfunction in mice with ischemic stroke only and ischemic stroke plus tibia fracture.PHA 568487 (1.25 mg/kg; i.p.; treated daily)-treated ischemic rats shows a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.Animal Model:C57BL/6J male mice (10-12 weeks old)
Dosage:PHA 568487 (PHA; 0.4 and 0.8 mg/kg);Methyllycaconitine (MLA; 4 and 6 mg/kg)
Administration:Injected intraperitoneally once on day 1, or twice on days 1 and 2, after pMCAO
Result:Injection of PHA (0.8 mg/kg) and MLA (6 mg/kg) on days 1 and 2 after pMCAO yielded the best effect on infarct volume and behavior tests.
Animal Model:Adult male Sprague-Dawley rats (297 6±8.3 g)
Dosage:1.25 mg/kg
Administration:I.p.;0.1 mL; treated daily
Result:Showed a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.
体外研究：
PHA 568487 increases anti-oxidant gene expression and decreases oxidative stress and phosphorylation of NF-κb p65. Methyllycaconitine (MLA) has the opposite effects.PHA increases anti-oxidant genes and NADPH oxidase expression associated with decreased phosphorylation of NF-kB p65 in microglia/macrophages.
PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.
体内研究：
PHA 568487 attenuates neuronal injury and behavioral dysfunction in mice with ischemic stroke only and ischemic stroke plus tibia fracture.PHA 568487 (1.25 mg/kg; i.p.; treated daily)-treated ischemic rats shows a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.Animal Model:C57BL/6J male mice (10-12 weeks old)
Dosage:PHA 568487 (PHA; 0.4 and 0.8 mg/kg);Methyllycaconitine (MLA; 4 and 6 mg/kg)
Administration:Injected intraperitoneally once on day 1, or twice on days 1 and 2, after pMCAO
Result:Injection of PHA (0.8 mg/kg) and MLA (6 mg/kg) on days 1 and 2 after pMCAO yielded the best effect on infarct volume and behavior tests.
Animal Model:Adult male Sprague-Dawley rats (297 6±8.3 g)
Dosage:1.25 mg/kg
Administration:I.p.;0.1 mL; treated daily
Result:Showed a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome.
体外研究：
PHA 568487 increases anti-oxidant gene expression and decreases oxidative stress and phosphorylation of NF-κb p65. Methyllycaconitine (MLA) has the opposite effects.PHA increases anti-oxidant genes and NADPH oxidase expression associated with decreased phosphorylation of NF-kB p65 in microglia/macrophages.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备